Search

Your search keyword '"Wang, Danbo"' showing total 147 results
Start Over Author "Wang, Danbo" Publication Year Range Last 3 years
Sorry, I don't understand your search. ×
147 results on '"Wang, Danbo"'

2. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer

Author

Li, Huayi, Peng, Zikun, Zhu, Jianqing, Zhao, Weidong, Huang, Yi, An, Ruifang, Zheng, Hong, Qu, Pengpeng, Wang, Li, Zhou, Qi, Wang, Danbo, Lou, Ge, Wang, Jing, Wang, Ke, Kong, Beihua, Xie, Xing, Yin, Rutie, Low, John, Rozita, Abdul Malik, Sen, Lim Chun, Meng, Yong Chee, Kiong, Kho Swee, Liu, Jihong, Liang, Zhiqing, Lv, Weiguo, Zhu, Yaping, Hu, Weiguo, Sun, Wei, Su, Jingya, Wang, Qiqi, Zang, Rongyu, Ma, Ding, and Gao, Qinglei

Published
2024
Full Text
View/download PDF

6. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial

Author

Wu, Xiaohua, Zhu, Jianqing, Yin, Rutie, Yang, Jiaxin, Liu, Jihong, Wang, Jing, Wu, Lingying, Liu, Ziling, Gao, Yunong, Wang, Danbo, Lou, Ge, Yang, Hongying, Zhou, Qi, Kong, Beihua, Huang, Yi, Chen, Lipai, Li, Guiling, An, Ruifang, Wang, Ke, Zhang, Yu, Yan, Xiaojian, Lu, Xin, Lu, Weiguo, Hao, Min, Wang, Li, Cui, Heng, Chen, Qionghua, Abulizi, Guzhalinuer, Huang, Xianghua, Tian, Xiaofei, Wen, Hao, Huang, Zhao, Dong, Juan, Zhang, Charlie, Hou, Jianmei, and Mirza, Mansoor R.

Published
2024
Full Text
View/download PDF

16. Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial

Author

Hu, Yingjie, Han, Yingyan, Shen, Yuanming, Chen, Jing, Chen, Yaheng, Chen, Yile, Tang, Junying, Xue, Min, Hong, Li, Cheng, Wenjun, Wang, Danbo, Liang, Zhiqing, Wang, Yifeng, Zhang, Qinghua, Xing, Hui, Zhang, Yu, Yi, Cunjian, Yu, Zhiying, Chen, Youguo, Cui, Manhua, Ma, Cailing, Yang, Hongying, Li, Ruizhen, Long, Ping, Zhao, Yu, Qu, Pengpeng, Tao, Guangshi, Yang, Lihua, Wu, Sufang, Liu, Zhihua, Yang, Ping, Lv, Weiguo, Xie, Xing, Ma, Ding, Wang, Hui, and Li, Kezhen

Published
2022
Full Text
View/download PDF

18. Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial.

Author

Gao, Qing-lei, primary, Zhu, Jianqing, additional, Zhao, Weidong, additional, Huang, Yi, additional, An, Ruifang, additional, Zheng, Hong, additional, Qu, Pengpeng, additional, Wang, Li, additional, Zhou, Qi, additional, Wang, Danbo, additional, Lou, Ge, additional, Wang, Jing, additional, Low, John, additional, Kong, Beihua, additional, Yin, Rutie, additional, Lv, Weiguo, additional, Liu, Jihong, additional, Sun, Wei, additional, Zang, Rongyu, additional, and Ma, Ding, additional

Published
2024
Full Text
View/download PDF

19. Efficacy and safety of combination therapy with envafolimab and lenvatinib in patients with endometrial cancer after failure of first-line platinum-based therapy.

Author

Wen, Hao, primary, Wu, Xiaohua, additional, Li, Qingshui, additional, Wu, Xiuhong, additional, Wang, Ke, additional, Zhang, Xiang, additional, Yang, Hongying, additional, Luo, Yanlin, additional, Gao, Yunong, additional, Xu, Qin, additional, Liu, Ziling, additional, Wang, Danbo, additional, Li, Xiumin, additional, Hu, Jianbing, additional, Xiao, Shen, additional, Qin, Lan, additional, Zhu, Di, additional, Xu, Siying, additional, Zou, Jing, additional, and She, Bin, additional

Published
2024
Full Text
View/download PDF

20. Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with PMMR status: Results from a multicenter, single-arm phase 2 study.

Author

Wu, Xiaohua, primary, Wang, Jing, additional, Wang, Danbo, additional, Li, Guiling, additional, Zhang, Jieqing, additional, Chen, Hongmin, additional, Yang, Hongying, additional, Zhou, Qi, additional, Wang, Ke, additional, Wu, Yumei, additional, Yi, Tienan, additional, Liu, Jihong, additional, Huang, Yi, additional, Bai, Yuxian, additional, Wang, Keming, additional, Jiang, Kui, additional, Lou, Hanmei, additional, An, Ruifang, additional, Li, Xiumin, additional, and Su, Weiguo, additional

Published
2024
Full Text
View/download PDF

21. Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinical trial (TQB2450-II-08).

Author

Wu, Xiaohua, primary, Chen, Xiaojun, additional, Wang, Ke, additional, Wang, Dong, additional, An, Ruifang, additional, Hou, Jianqing, additional, Yang, Ying, additional, Wang, Danbo, additional, Qu, Pengpeng, additional, Zhang, Bingzhong, additional, Duan, Wei, additional, Li, Xiumin, additional, Zang, Ai-min, additional, Yu, Guohua, additional, Lou, Hanmei, additional, Yao, Desheng, additional, Wang, Shuzhen, additional, Yan, Dong, additional, Li, Liang, additional, and Liu, Xiaowei, additional

Published
2024
Full Text
View/download PDF

25. Macrocycle‐Based Hierarchically Porous Hydrogen‐Bonded Organic Frameworks.

Author

Wang, Hui, Wang, Danbo, Wu, Yumin, and Zhao, Yingjie

Subjects
*POROUS materials, *POROSITY
Abstract

Hydrogen‐bonded organic frameworks (HOFs) are porous crystalline materials. The pores in HOFs are usually non‐covalent extrinsic pores constructed through the formation of the framework. Supramolecular macrocycles with intrinsic pores in their structures are good candidates for constructing HOFs with intrinsic pores from the macrocycles themselves, thus leading to hierarchically porous structures. Combining the macrocycle and HOFs will endow these hierarchically porous materials with enhanced properties and special functionalities. This review summarizes recent advances in macrocycle‐based HOFs, including the macrocycles used for constructing HOFs, the hierarchically porous structures of the HOFs, and the applications induced by the hierarchically HOFs porous structures. This review provides insights for future research on macrocycle‐based hierarchically porous HOFs and the appropriate applications of the unique structures. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. A nitrogen-rich graphdiyne containing hexaazatrinaphthylene for high-performance lithium-ion batteries.

Author

Hou, Jiaheng, Wang, Danbo, Chao, Menghuan, Zhang, Lin, Liu, Hui, and Zhao, Yingjie

Abstract

A nitrogen-rich graphdiyne (HATN-GDY) material containing electrochemical active hexaazatrinaphthylene units was successfully prepared. HATN-GDY exhibits a superior specific capacity of 2139 mA h g−1 and firm long-term stability due to the unique 2D π-conjugated structure and the large in-plane N-cavities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Effectiveness of a single low‐dose computed tomography screening for lung cancer: A population‐based perspective cohort study in China.

Author

Yu, Zhifu, Ni, Ping, Yu, Huihui, Zuo, Tingting, Liu, Yunyong, and Wang, Danbo

Subjects
LUNG cancer, COMPUTED tomography, EARLY detection of cancer, PROPORTIONAL hazards models, COHORT analysis
Abstract

The purpose of this perspective cohort study was to evaluate the effectiveness of low‐dose computed tomography (LDCT) screening for lung cancer in China. This study was conducted under the China Urban Cancer Screening Program (CanSPUC). The analysis was based on participants aged 40 to 74 years from 2012 to 2019. A total of 255 569 eligible participants were recruited in the study. Among the 58 136 participants at high risk of lung cancer, 20 346 (35.00%) had a single LDCT scan (defined as the screened group) and 37 790 (65.00%) not (defined as the non‐screened group). Overall, 1162 participants were diagnosed with lung cancer at median follow‐up time of 5.25 years. The screened group had the highest cumulative incidence of lung cancer and the non‐screened group had the highest cumulative lung cancer mortality and all‐cause cumulative mortality. We performed inverse probability weighting (IPW) to account for potential imbalances, and Cox proportional hazards model to estimate the weighted association between mortality and LDCT scans. After IPW adjusted with baseline characteristics, the lung cancer incidence density was significantly increased (37.0% increase) (HR1.37 [95%CI 1.12‐1.69]), lung cancer mortality was decreased (31.0% decrease) (HR0.69 [95%CI 0.49‐0.97]), and the all‐cause mortality was significantly decreased (23.0% lower) (HR0.77 [95% CI 0.68‐0.87]) in the screened group. In summary, a single LDCT for lung cancer screening will reduce the mortality of lung cancer and all‐cause mortality in China. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. CD48 suppresses proliferation and migration as an immune-related prognostic signature in the cervical cancer immune microenvironment.

Author

Ma, Yue, Yang, Zhuo, Liu, Jing, and Wang, Danbo

Abstract

Cervical cancer (CC) is one of the most common malignant tumors in gynecology. Immunotherapy and targeted therapy are two particularly effective treatments. In this study, weighted gene co-expression network analysis and CIBERSORT algorithm that quantifies the composition of immune cells were used to analyze CC expression data based on the GEO database and identify modules related to T cells. Five candidate hub genes were identified by tumor-infiltrating immune cells estimation and Kaplan–Meier survival analysis according to CC data from The Cancer Genome Atlas (TCGA). Chemotherapeutic response, methylation, and gene mutation analyses were implemented so that the five candidate hub genes identified may be the potential biomarkers and therapeutic targets which were related to T cell infiltration. Moreover, the results of RT-qPCR revealed that CD48 was a tumor suppressor gene, which was negatively correlated with CC stages, lymph node metastasis, and differentiation. Furthermore, the functional study verified that the interference of CD48 was able to boost the proliferation and migration ability in vitro and the growth of transplanted tumors in vivo. Overall, we identified molecular targets related to immune infiltration and prognosis, regarded CD48 as a key molecule involved in the progression of CC, thus providing new insights into the development of molecular therapy and immunotherapeutics against CC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Abstract CT079: Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial

Author

Gao, Qinglei, primary, Wang, Jing, additional, Xu, Qin, additional, Tang, Ying, additional, Zhang, Jieqing, additional, Chang, Baoping, additional, Xia, Bairong, additional, Duan, Wei, additional, Wang, Danbo, additional, Zhu, Lijing, additional, An, Ruifang, additional, Zhang, Guonan, additional, Tang, Yaling, additional, Huang, Jianli, additional, Zhang, Xiang, additional, Qiu, Hui, additional, Ji, Wenting, additional, Li, Li, additional, Zhu, Jianqing, additional, and Ma, Ding, additional

Published
2023
Full Text
View/download PDF

31. Supplementary Information from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

Author

An, Jusheng, primary, Tang, Jie, primary, Li, Benjamin X., primary, Xiong, Huihua, primary, Qiu, Hui, primary, Luo, Lin, primary, Wang, Li, primary, Wang, Danbo, primary, Zhou, Qi, primary, Xu, Qin, primary, Song, Honglin, primary, Zhang, Yunyan, primary, Zhang, Hongping, primary, Li, Yujie, primary, Yu, Xiaohui, primary, Zhang, Jing, primary, Ng, Rachel, primary, Zhao, Wayne, primary, Wong, Michael, primary, Dai, Xiangrong, primary, Li, Guiling, primary, and Wu, Lingying, primary

Published
2023
Full Text
View/download PDF

32. Appendix Table A1 from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

Author

An, Jusheng, primary, Tang, Jie, primary, Li, Benjamin X., primary, Xiong, Huihua, primary, Qiu, Hui, primary, Luo, Lin, primary, Wang, Li, primary, Wang, Danbo, primary, Zhou, Qi, primary, Xu, Qin, primary, Song, Honglin, primary, Zhang, Yunyan, primary, Zhang, Hongping, primary, Li, Yujie, primary, Yu, Xiaohui, primary, Zhang, Jing, primary, Ng, Rachel, primary, Zhao, Wayne, primary, Wong, Michael, primary, Dai, Xiangrong, primary, Li, Guiling, primary, and Wu, Lingying, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table from Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)

Author

Gao, Qinglei, primary, Zhu, Jianqing, primary, Zhao, Weidong, primary, Huang, Yi, primary, An, Ruifang, primary, Zheng, Hong, primary, Qu, Pengpeng, primary, Wang, Li, primary, Zhou, Qi, primary, Wang, Danbo, primary, Lou, Ge, primary, Wang, Jing, primary, Wang, Ke, primary, Low, John, primary, Kong, Beihua, primary, Rozita, Abdul Malik, primary, Sen, Lim Chun, primary, Yin, Rutie, primary, Xie, Xing, primary, Liu, Jihong, primary, Sun, Wei, primary, Su, Jingya, primary, Zhang, Chunyi, primary, Zang, Rongyu, primary, and Ma, Ding, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

Author

Wu, Xiaohua, primary, Zhu, Jianqing, primary, Wang, Jing, primary, Lin, Zhongqiu, primary, Yin, Rutie, primary, Sun, Wei, primary, Zhou, Qi, primary, Zhang, Songling, primary, Wang, Danbo, primary, Shi, Hong, primary, Gao, Yunong, primary, Huang, Yi, primary, Li, Guiling, primary, Wang, Xiuli, primary, Cheng, Ying, primary, Lou, Ge, primary, Gao, Qinglei, primary, Wang, Li, primary, Du, Xiuping, primary, Pan, Mei, primary, Mu, Xiyan, primary, Li, Li, primary, Li, Miao, primary, Mu, Song, primary, and Kong, Beihua, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

Author

Wu, Xiaohua, primary, Zhu, Jianqing, primary, Wang, Jing, primary, Lin, Zhongqiu, primary, Yin, Rutie, primary, Sun, Wei, primary, Zhou, Qi, primary, Zhang, Songling, primary, Wang, Danbo, primary, Shi, Hong, primary, Gao, Yunong, primary, Huang, Yi, primary, Li, Guiling, primary, Wang, Xiuli, primary, Cheng, Ying, primary, Lou, Ge, primary, Gao, Qinglei, primary, Wang, Li, primary, Du, Xiuping, primary, Pan, Mei, primary, Mu, Xiyan, primary, Li, Li, primary, Li, Miao, primary, Mu, Song, primary, and Kong, Beihua, primary

Published
2023
Full Text
View/download PDF

46. Neoadjuvant Chemotherapy for Patients with International Federation of Gynecology and Obstetrics Stages IB3 and IIA2 Cervical Cancer: A Multicenter Prospective Trial

Author

Hu, Yingjie, primary, Han, Yingyan, additional, Shen, Yuanming, additional, Chen, Jing, additional, Chen, Yaheng, additional, Chen, Yile, additional, Tang, Junying, additional, Xue, Min, additional, Hong, Li, additional, Cheng, Wenjun, additional, Wang, Danbo, additional, Liang, Zhiqing, additional, Wang, Yifeng, additional, Zhang, Qinghua, additional, Xing, Hui, additional, Zhang, Yu, additional, Yi, Cunjian, additional, Yu, Zhiying, additional, Chen, Youguo, additional, Cui, Manhua, additional, Ma, Cailing, additional, Yang, Hongying, additional, Li, Ruizhen, additional, Long, Ping, additional, Zhao, Yu, additional, Qu, Pengpeng, additional, Tao, Guangshi, additional, Yang, Lihua, additional, Wu, Sufang, additional, Liu, Zhihua, additional, Yang, Ping, additional, Lv, Weiguo, additional, Xie, Xing, additional, Ma, Ding, additional, Wang, Hui, additional, and Li, Kezhen, additional

Published
2022
Full Text
View/download PDF

47. Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

Author

An, Jusheng, primary, Tang, Jie, additional, Li, Benjamin X., additional, Xiong, Huihua, additional, Qiu, Hui, additional, Luo, Lin, additional, Wang, Li, additional, Wang, Danbo, additional, Zhou, Qi, additional, Xu, Qin, additional, Song, Honglin, additional, Zhang, Yunyan, additional, Zhang, Hongping, additional, Li, Yujie, additional, Yu, Xiaohui, additional, Zhang, Jing, additional, Ng, Rachel, additional, Zhao, Wayne, additional, Wong, Michael, additional, Dai, Xiangrong, additional, Li, Guiling, additional, and Wu, Lingying, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results